Greatmark Investment Partners Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.5% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 58,410 shares of the biopharmaceutical company’s stock after buying an additional 7,845 shares during the period. Gilead Sciences accounts for approximately 1.6% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 21st largest position. Greatmark Investment Partners Inc.’s holdings in Gilead Sciences were worth $3,967,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Rhumbline Advisers boosted its stake in Gilead Sciences by 2.1% in the first quarter. Rhumbline Advisers now owns 2,258,902 shares of the biopharmaceutical company’s stock valued at $153,425,000 after buying an additional 46,707 shares in the last quarter. Stevens First Principles Investment Advisors boosted its stake in shares of Gilead Sciences by 1.3% in the first quarter. Stevens First Principles Investment Advisors now owns 50,175 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 635 shares during the period. Empire Life Investments Inc. purchased a new stake in shares of Gilead Sciences during the first quarter worth approximately $4,380,000. Capital One National Association boosted its stake in shares of Gilead Sciences by 2.5% in the first quarter. Capital One National Association now owns 20,219 shares of the biopharmaceutical company’s stock worth $1,373,000 after buying an additional 484 shares during the period. Finally, Trust Investment Advisors boosted its stake in shares of Gilead Sciences by 10.3% in the first quarter. Trust Investment Advisors now owns 6,420 shares of the biopharmaceutical company’s stock worth $436,000 after buying an additional 600 shares during the period. 73.99% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (GILD) traded down 1.63% during midday trading on Friday, reaching $73.16. The company’s stock had a trading volume of 14,948,578 shares. The stock has a market cap of $95.55 billion, a price-to-earnings ratio of 7.95 and a beta of 1.21. The stock’s 50 day moving average price is $70.60 and its 200-day moving average price is $68.59. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the company posted $3.08 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s payout ratio is currently 22.58%.

TRADEMARK VIOLATION WARNING: “Greatmark Investment Partners Inc. Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/04/greatmark-investment-partners-inc-has-3-97-million-position-in-gilead-sciences-inc-nasdaqgild-updated-updated-updated.html.

A number of equities research analysts have commented on GILD shares. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price objective for the company in a research note on Tuesday, April 18th. Jefferies Group LLC reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Thursday, April 6th. J P Morgan Chase & Co reiterated an “overweight” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Thursday, April 6th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a report on Tuesday, May 2nd. Finally, Barclays PLC restated an “overweight” rating and issued a $85.00 target price (down from $90.00) on shares of Gilead Sciences in a research note on Sunday, April 23rd. Eleven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $80.31.

In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold a total of 216,609 shares of company stock valued at $15,891,851 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.